Astra, Glaxo Covid Antibodies Show Some Omicron Effect in Mice
This article is for subscribers only.
AstraZeneca Plc and GlaxoSmithKline Plc’s Covid antibody therapies elicited some protection against the omicron variant and its newest mutation, known as BA.2, in mice.
The treatments lost potency but they reduced the viral burden and limited lung inflammation caused by the virus, scientists from the Washington University School of Medicine reported on the bioRxiv server. The findings weren’t peer-reviewed.